Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems • Medical Devices & Mechanical Engineering
7 pending office actions • 7 clients • 7 examiners • 5 art units • 0 of 7 (0%) have an AI response strategy ready
Rivkin Radler LLP has managed 264 career applications with a focus on the Biotechnology & Pharmaceuticals technology area. The firm maintains a resolved allowance rate of 78.95 percent.
During the prosecution process, the firm averages 2.47 office actions per allowance. There are currently 7 pending office actions requiring attention. These metrics provide a view of the firm's 78.95 percent allowance rate relative to the 2.47 office actions typically required per allowance.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (14%) |
| Multi-statute (no §101) | 6 (86%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
| LEE, ANDREW P | 1 | 48.3% | +23.1% |
| DAVIS, CASSANDRA HOPE | 1 | 59.3% | +25.9% |
| DALE, ABIGAYLE ANN | 1 | 41.7% | +68.8% |
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.5% |
| MOORE, SUSANNA | 1 | 68.1% | +31.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268555 | Side Port For Addition Of Multiple Drugs To A Nebulizer | DALE, ABIGAYLE ANN | 44d overdue |
| 17792369 | PURIFICATION METHOD OF PROGESTERONE | MOORE, SUSANNA | 24d overdue |
| 18041827 | EXTRACORPOREAL CLEARING TRAPS BASED ON INVERSE ELECTRON DEMAND DIELS-ALDER CYCLOADDITION FOR (PRE)-TARGETED THERAPY AND DIAGNOSTICS | SCHLIENTZ, LEAH H | 39d |
| 18781717 | USE OF SECOND NEAR-INFRARED ORGANIC FLUORESCENT COMPOUND IN PREPARATION OF BIOIMAGING CONTRAST AGENT AND IN VASCULAR FLUORESCENCE IMAGING | DONOHUE, SEAN R | — |
| 18703281 | PEPTIDE-COUPLED ALGINATE GELS COMPRISING RADIONUCLIDES | CRAIG, KAILA ANGELIQUE | — |
| 18490503 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | LEE, ANDREW P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268555 | Side Port For Addition Of Multiple Drugs To A Nebulizer | DALE, ABIGAYLE ANN | 44d overdue |
| 17792369 | PURIFICATION METHOD OF PROGESTERONE | MOORE, SUSANNA | 24d overdue |
| 18041827 | EXTRACORPOREAL CLEARING TRAPS BASED ON INVERSE ELECTRON DEMAND DIELS-ALDER CYCLOADDITION FOR (PRE)-TARGETED THERAPY AND DIAGNOSTICS | SCHLIENTZ, LEAH H | 39d |
| 18781717 | USE OF SECOND NEAR-INFRARED ORGANIC FLUORESCENT COMPOUND IN PREPARATION OF BIOIMAGING CONTRAST AGENT AND IN VASCULAR FLUORESCENCE IMAGING | DONOHUE, SEAN R | — |
| 18703281 | PEPTIDE-COUPLED ALGINATE GELS COMPRISING RADIONUCLIDES | CRAIG, KAILA ANGELIQUE | — |
| 18490503 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | LEE, ANDREW P | — |
| 18234490 | Simulated Fireplace | DAVIS, CASSANDRA HOPE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Inner Mongolia University | 1 |
| Blue Wave Therapeutics GmbH | 1 |
| Aleta Neuroscience, LLC | 1 |
| ESCEA LIMITED | 1 |
| InspiRx, Inc. | 1 |
| UNIVERSITY OF COPENHAGEN | 1 |
| Zhejiang Shenzhou | 1 |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 3631 | 1 |
| 3785 | 1 |
| 1618 | 1 |
| 1624 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18781717 | USE OF SECOND NEAR-INFRARED ORGANIC FLUORESCENT COMPOUND IN PREPARATION OF BIOIMAGING CONTRAST AGENT AND IN VASCULAR FLUORESCENCE IMAGING | Inner Mongolia University | DONOHUE, SEAN R | §102§103§112 | Non-Final OA | — | Pending | Jul 23, 2024 | |
| 18703281 | PEPTIDE-COUPLED ALGINATE GELS COMPRISING RADIONUCLIDES | Blue Wave Therapeutics GmbH | CRAIG, KAILA ANGELIQUE | §103§112 | Non-Final OA | — | Pending | Apr 19, 2024 | |
| 18490503 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | Aleta Neuroscience, LLC | LEE, ANDREW P | 1691 | §102§103 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18234490 | Simulated Fireplace | Escea Limited | DAVIS, CASSANDRA HOPE | 3631 | §112 | Final Rejection | — | Pending | Aug 16, 2023 |
| 18268555 | Side Port For Addition Of Multiple Drugs To A Nebulizer | Inspirx, Inc. | DALE, ABIGAYLE ANN | 3785 | §102§103§112 | Final Rejection | 44d overdue | Pending | Jun 20, 2023 |
| 18041827 | EXTRACORPOREAL CLEARING TRAPS BASED ON INVERSE ELECTRON DEMAND DIELS-ALDER CYCLOADDITION FOR (PRE)-TARGETED THERAPY AND DIAGNOSTICS | UNIVERSITY OF COPENHAGEN | SCHLIENTZ, LEAH H | 1618 | §103§112 | Non-Final OA | 39d | Pending | Feb 16, 2023 |
| 17792369 | PURIFICATION METHOD OF PROGESTERONE | Zhejiang Shenzhou Pharmaceutical Company Limited | MOORE, SUSANNA | 1624 | §103§112 | Final Rejection | 24d overdue | Pending | Jul 12, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial